In summary, our findings showed that dual blockade of PD-1 signaling and PGE2 during priming of tumor-specific CTLs with tumor-derived APCs effectively recovered CTLs responses to levels that were detected with peripheral blood derived APCs. The gene discussed is PDCD1; the disease is neoplasm.